**BREATHTEC BIOMEDICAL INC.**Suite 890, 789 West Pender Street  
Vancouver, British Columbia, Canada V6C 1H2

**BREATHTEC BIOMEDICAL APPOINTS GUY LATORRE AS CHIEF EXECUTIVE OFFICER**

VANCOUVER, BRITISH COLUMBIA – June 20, 2016 – [Breathtec BioMedical, Inc](http://breathtecbiomedical.com/). (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infections and life threatening diseases, is pleased to announce the appointment of Mr. Guy LaTorre as Chief Executive Officer of the Company. Mr. LaTorre was previously an advisor to the Company on product development and licensing matters.

Mr. LaTorre brings over 25 years of experience in the development and commercialization of medical devices and consumer products in a startup company environment. Guy was a co-founder and Vice President of Business Development at [Novamin Technology Inc](http://www.gainesville.com/article/20100523/ARTICLES/5231002) where he was responsible for identifying and managing the Company’s relationships with its key clients in the dental products field, including product development of in-office and at-home use products using the company’s proprietary ingredient. In that role, he formed and managed product development partnerships between NTI and the leading marketers of professional dental products, including Dentsply Corp, 3M Corp, Sultan Healthcare, Sunstar and others until the company was sold to GlaxoSmithKline (GSK) in 2010 for USD $[135 million](http://www.gainesville.com/article/20100523/ARTICLES/5231002).

Previously, he was the Director of Scientific Affairs at USBiomaterials Corp. which developed and sold synthetic bone grafting products for use in dental, head, neck and orthopedic surgeries. His responsibilities also included product development, manufacturing and business development activities. Prior to USBiomaterials, Mr. LaTorre was the Laboratory Manager of the University of Florida Advanced Materials Research Center where he was responsible for the managed transfer of licensed university technologies to private startup companies. Guy has been the author or co-author of over fifty scientific publications and holds seven US patents with associated filings worldwide.

“I am thoroughly delighted to undertake this opportunity with Breathtec during this particularly important period of growth,” Comments Mr. LaTorre, who further notes, “The Company is nurturing an expanding pipeline of innovative technology during a period of intense interest in the emerging field of breath analysis. The focus here at Breathtec is on early stage, accessible and non-invasive diagnostics across a wide range of diseases. Successful commercialization of this technology is poised to offer a truly profound impact on personal health care delivery. So it’s a great pleasure to join with a team that brings such a strong technical and clinical approach to its business.”

“Speaking on behalf of the Company, we are very pleased to attract an executive of Guy’s caliber and particular skill set to join our growing team,” Notes Mr. Kal Malhi, Breathtec President. “His previous service as a medical device executive focused on building and operating startups, combined with his operational experience in commercializing novel technologies, and in conducting clinical trials to achieve FDA compliance in the medical device sector will be a major asset for Breathtec.” Mr. Malhi continues, “I’d also like to take this opportunity to thank Dr. Michael Costanzo for his term of service as outgoing CEO and am delighted to announce his new role as Breathtec’s Chief Technology Officer where we are certain his contributions will help guide and propel our clinical and commercialization efforts.”

**ON BEHALF OF THE BOARD**

"Kal Malhi"  
President & Director

**For further information, please contact:**

Kal Malhi

President and Director

[Breathtec BioMedical, Inc](http://breathtecbiomedical.com/)

or

Core Capital Partners   
Telephone: 604-566-9233  
Email: [investors@ccpartnersinc.com](mailto:investors@ccpartnersinc.com)

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release*.

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*